Agilent Technologies reported a second-quarter net loss of $146m, with its semiconductor test equipment and component businesses up, but other areas, including life sciences and chemical analysis, remained flat.
Not including $74m in net restructuring charges and intangibles amortisation that were part of the generally accepted accounting principles loss, Agilent posted a net loss of $72m, with revenue of $1.47bn and reported orders of $1.53bn for the quarter ending 30 April.
Agilent is forecasting third-quarter revenue between $1.45bn and $1.55 bn.
In life sciences and chemical analysis during the second quarter, the company had orders of $280m, down 2% from the same period the previous year, but up 4% sequentially.
Life sciences orders were down 4% for the same period the previous year and up 1% from the previous quarter. Life sciences and chemical analysis revenue was $286m, up 5% from a year ago and 4% from the first quarter.
Operating profits for that business unit were down $14m from the first quarter, following a seasonal pattern similar to last year. Higher revenue did not translate into more profit because of increased research and development spending in life sciences, and higher temporary IT costs because of customer relationship management implementation.